Triple-negative breast cancer (TNBC) represents a very heterogeneous group of breast diseases. Currently, the backbone of therapy for TNBC is mainly chemotherapy as there are no effective specific targeted agents approved to treat TNBC. Despite initial responses to chemotherapy, resistance frequently and rapidly develops and metastatic TNBC has a poor prognosis. Therefore, new targeted strategies are, accordingly, urgently needed. This article discusses the recent developments in targeted agents explored for TNBC, aiming to offer novel therapeutic strategies that can potentially assist in designing personalized therapeutics in the future as well as provide the basis for further research in an attempt to target TNBC.
CITATION STYLE
Zhang, J. F., Liu, J., Wang, Y., & Zhang, B. (2016, October 21). Novel therapeutic strategies for patients with triple-negative breast cancer. OncoTargets and Therapy. Dove Medical Press Ltd. https://doi.org/10.2147/OTT.S105716
Mendeley helps you to discover research relevant for your work.